Abstract:With a growing market size, and a large variety of applications, monoclonal antibody technology adoption and clinical usage is at an all-time high. This review article seeks to explore 10 monoclonal antibodies (mAbs) and their mechanism of action, specifically their pharmacodynamic (PD) and pharmacokinetic (PK) properties, and use a machine learning model with various parameters to assess whether the mAb has adequate bioavailability when delivered subcutaneously. This is an investigation of drug optimization and patient outcomes when transitioning from traditional IV administrations to subcutaneous injections. The machine learning model is an extension based on a paper by Han Lou and Michael Hageman, , where they took 10 mAbs and analyzed 45 different features. To further extend this paper, we took an additional 10 monoclonal antibodies that were delivered subcutaneously, and took into account their dosage concentration as an extension to traditional PK properties. By including additional mAbs and dosage, a more sophisticated model can be produced with high scalability to deep learning modalities.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate whether monoclonal antibodies (mAbs) have sufficient bioavailability when injected subcutaneously through a machine - learning model, in order to optimize drugs and improve patient treatment outcomes. Specifically, the study aims to: 1. **Explore the pharmacodynamics (PD) and pharmacokinetics (PK) characteristics of monoclonal antibodies**: In particular, for 10 monoclonal antibodies, analyze their mechanisms and their behavior in vivo in detail. 2. **Develop and validate prediction models**: Based on 45 different characteristic parameters, use machine - learning methods (such as Support Vector Machine, SVM) to predict the bioavailability of monoclonal antibodies when injected subcutaneously. This model extends the previous research of Han Lou and Michael Hageman by adding more types of monoclonal antibodies and dose - concentration data. 3. **Optimize the route of administration**: Shift from the traditional intravenous injection to subcutaneous injection and explore the impact of this shift on drug optimization and patient prognosis. Subcutaneous injection has the advantages of being more convenient and having higher patient compliance, but it is necessary to ensure that its bioavailability is high enough. 4. **Improve the scalability and accuracy of the model**: By adding more monoclonal antibodies and dose information, construct a more complex and efficient prediction model that can better adapt to the deep - learning modality and provide references for future drug research and development. ### Main research contents - **Data collection**: Collected 45 characteristic parameters of 23 monoclonal antibodies from databases such as DrugBank and PubMed, including amino acid sequences, formulation concentrations, pH values, etc. - **Data analysis**: Use principal component analysis (PCA) for dimension reduction, extract the most relevant features, and show the impact of each feature on the principal components through a heat map. - **Model construction**: Use Support Vector Machine (SVM) for binary - classification prediction. Define bioavailability greater than or equal to 70% as "sufficient" and less than 70% as "insufficient". Tested the effects of the linear kernel, the radial basis function kernel, and the polynomial kernel respectively, and selected the best model through cross - validation. ### Conclusion This study improves the existing machine - learning model by introducing more monoclonal antibodies and dose information, enhances the accuracy and reliability of predicting the bioavailability of subcutaneous monoclonal antibodies, and provides a scientific basis for further optimizing drug - delivery methods.

Potential Opportunities of Modeling Bioavailability for Monoclonal Antibodies: An Overview of mAbs and the current challenges of mAb development

Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach

Analyze Impact of Tumor-Associated Kinetics on Antibody Delivery in Solid Tumors with a Physiologically Based Pharmacokinetics/pharmacodynamics Model.

Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice

The role of initial lymphatics in the absorption of monoclonal antibodies after subcutaneous injection

A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph Nodes

Monoclonal antibodies: From magic bullet to precision weapon

A scoping review of supervised learning modelling and data-driven optimisation in monoclonal antibody process development

Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework

Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery

Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions

Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies

The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Pharmacokinetics of Monoclonal Antibodies

Development of in vitro biopharmaceutics tools for predicting the bioavailability of subcutaneously injected monoclonal antibodies and oligonucleotides

Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy

A deep learning-aided multi-objective optimization of a downstream process for production of monoclonal antibody products

Assessing Physicochemical Stability of Monoclonal Antibodies in a Simulated Subcutaneous Environment

Application of Pharmacometrics in Advancing the Clinical Research of Antibody-Drug Conjugates: Principles and Modeling Strategies

Best practices for machine learning in antibody discovery and development